K. Tsao

发表

Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP.

A. Neri, J. E. Losardo, D. Waugh, 1994, The Journal of biological chemistry.

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.

Margaret S. Wu, Yun-ping Zhou, A. Howard, 2018, ACS medicinal chemistry letters.

Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.

Margaret S. Wu, Yun-ping Zhou, A. Howard, 2012, ACS medicinal chemistry letters.

Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.

Yun-ping Zhou, E. Sherer, A. Howard, 2014, ACS medicinal chemistry letters.

Prenatal diagnostic options in cystic fibrosis.

K. Tsao, C. Denning, R. Mulivor, 1988, American journal of obstetrics and gynecology.

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.

G. Meneses‐Lorente, M. Rigby, K. Tsao, 2006, Bioorganic & medicinal chemistry letters.

2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.

L. Gantert, R. DeVita, R. Hargreaves, 2013, Journal of medicinal chemistry.

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2014, ACS medicinal chemistry letters.

Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.

S. Boyce, R. DeVita, J. Demartino, 2010, Bioorganic & medicinal chemistry letters.

Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.

P. Davies, S. Boyce, M. Reibarkh, 2010, Bioorganic & medicinal chemistry letters.

Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.

S. Boyce, R. DeVita, J. Demartino, 2008, Bioorganic & medicinal chemistry.

Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.

R. DeVita, K. Tsao, S. Mills, 2007, Bioorganic & medicinal chemistry letters.

Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.

Yun-ping Zhou, E. Sherer, A. Howard, 2015, Bioorganic & medicinal chemistry letters.

The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.

R. DeVita, H. Burns, R. Hargreaves, 2007, Bioorganic & medicinal chemistry letters.

Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608

G. Bentley, K. Tsao, R. Kilburn, 2003, Neuropharmacology.

2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution.

K. Tsao, C. Swain, G. Hollingworth, 2001, Bioorganic & medicinal chemistry letters.

2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent.

K. Tsao, C. Swain, G. Hollingworth, 2001, Bioorganic & medicinal chemistry letters.

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.

Margaret S. Wu, Rebecca T. Ruck, M. Reibarkh, 2012, ACS medicinal chemistry letters.

Human neuroblastoma metastases in a nude mouse model: tumor progression and onc gene amplification.

K. Tsao, F. Lalatta, F. Gilbert, 1988, Progress in clinical and biological research.

Tetrahydroindolizinone NK1 antagonists.

R. DeVita, K. Tsao, G. Morriello, 2010, Bioorganic & medicinal chemistry letters.

NK1 antagonists based on seven membered lactam scaffolds.

Alan Wheeldon, Maria Dominguez, U. Gerhard, 2006, Bioorganic & medicinal chemistry letters.

Novel lactam NK1 antagonists with anti-emetic activity.

K. Tsao, R. Kilburn, C. Swain, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.

Alan Wheeldon, K. Tsao, C. Swain, 2006, Bioorganic & medicinal chemistry letters.

4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II.

K. Tsao, C. Swain, G. Hollingworth, 2002, Bioorganic & medicinal chemistry letters.

Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.

J. Metzger, M. Maccoss, D. Macintyre, 2006, Bioorganic & medicinal chemistry letters.

Modulation of basal and stress‐induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L‐822429

F. Ferraguti, N. Singewald, K. Tsao, 2008, Journal of neurochemistry.

Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface.

D. Fry, R. Palermo, V. Madison, 1995, Biochemistry.

Characterization of DNA-protein interactions within a distal regulatory element upstream of a mammalian housekeeping gene promoter.

N. LeLeiko, M. Walsh, K. Tsao, 1992, The Journal of biological chemistry.

Balancing the production of two recombinant proteins in Escherichia coli by manipulating plasmid copy number: high-level expression of heterodimeric Ras farnesyltransferase.

D. Waugh, K. Tsao, 1997, Protein expression and purification.

Site-specific, enzymatic biotinylation of recombinant proteins in Spodoptera frugiperda cells using biotin acceptor peptides.

D. Waugh, K. Tsao, S. Duffy, 1998, Analytical biochemistry.

A versatile plasmid expression vector for the production of biotinylated proteins by site-specific, enzymatic modification in Escherichia coli.

H. Michel, D. Waugh, K. Tsao, 1996, Gene.

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Margaret S. Wu, Yun-ping Zhou, E. Sherer, 2015, ACS medicinal chemistry letters.

Chemical shift assignments and folding topology of the Ras-binding domain of human Raf-1 as determined by heteronuclear three-dimensional NMR spectroscopy.

D. Fry, D. Waugh, J. Scheffler, 1994, Biochemistry.

Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.

R. DeVita, R. Hargreaves, K. Tsao, 2009, Journal of medicinal chemistry.

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.

M. Rigby, K. Tsao, F. Murray, 2006, Bioorganic & medicinal chemistry letters.